Clinical trials: Myocardial Fibrosis
Primary Biliary Cholangitis, Cardiovascular Abnormalities
Early Identification of Myocardial Impairment in PBC
Primary biliary cholangitis (PBC) is a chronic inflammatory liver disease leading to cirrhosis. Researches reported patients with PBC may involve abnormalities on skeleton, thyroid and exocrine glands.
- Trial name
- EARLY-MYO-PBC (NCT03545672)
- Testing
- CMR examination
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
ST Elevation Myocardial Infarction
Relationship Between Left Ventricular Remodeling, Coronary Endothelial Function and Myocardial Fibrosis Using Positron Emission Tomography in Patients With ST-elevation Myocardial Infarction
Left ventricular remodeling is a common complication in patients with ST-elevation myocardial infarction (STEMI ) and may lead to heart failure.
- Trial name
- REMOD-TEP (NCT02789098)
- Testing
- (15)-O water positron emission tomography and Biomarkers
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Caen
Heart Failure and Preserved Ejection Fraction, Heart Failure
Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure
The goal of this clinical trial is to evaluate the impact of Finerenone on myocardial remodeling in patients with diabetic kidney disease (DKD) and heart failure with a left ventricular ejection fraction (LVEF) ≥ 40%.
- Conditions
- Heart Failure and Preserved Ejection Fraction, Heart Failure, Heart Failure and Mildly Reduced Ejection Fraction
- Trial name
- FINE-REMODEL (NCT07442448)
- Testing
- Finerenone
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Cathay General Hospital
Cushing's Syndrome Cardiomyopathy
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Pathophysiology of Cushing's Syndrome (CS) cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several…
- Trial name
- ERGO (NCT02611258)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Andrea M. Isidori
Type 2 Diabetes, Cardiovascular Risk
Canagliflozin and Myocardial Fibrosis
Recently, large clinical intervention studies have demonstrated the cardiovascular protective effects on of sodium-glucose cotransporter 2 inhibitors (SGLT2i) such as empagliflozin, dapagliflozin, and canagliflozin in reduction…
- Trial name
- CANA-DIA-FIB (NCT05367063)
- Testing
- Canagliflozin 100mg or Sitagliptin 100mg
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Carrier of Duchenne Muscular Dystrophy
Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-study
Carriers of Duchenne muscular dystrophy (DMD) often have no severe symptoms of the scelet muscles, but they may develop a poor heart function due to the involvement of the heart muscle.
- Trial name
- NCT01712152
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Hospital Rudolfstiftung
Severe Symptomatic Aortic Stenosis
Microvascular Function in Patients Undergoing Transcatheter Aortic Valve Implant (TAVI) for Severe Symptomatic Aortic Stenosis: Association With Myocardial Fibrosis
Microvascular function in patients undergoing Transcatheter Aortic Valve Implant (TAVI) for severe symptomatic aortic stenosis: association with myocardial fibrosis
- Trial name
- NCT05326126
- Testing
- coronary physiology
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Matteo Montorfano
Aortic Stenosis, Severe
MRI in Randomised Cohorts of Asymptomatic AS
Aortic stenosis is narrowing of the aortic valve, and is the commonest type of valve disease requiring surgery. Current guidelines recommend waiting till patients develop symptoms (chest pain, breathlessness and dizzy…
- Trial name
- NCT05178368
- Testing
- Surgical/ Transcatheter aortic valve replacement
- Where
- United Kingdom
- Volunteers
- 202 people
- Sponsor
- University of Leicester
Breast Cancer, Myocardial Fibrosis
Losartan in Prevention of Radiation-Induced Heart Failure
This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer.
- Conditions
- Breast Cancer, Myocardial Fibrosis, Radiation-Induced Fibrosis
- Trial name
- NCT05607017
- Testing
- Losartan, Radiation Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital